Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma
Phase 2 Unknown
35 enrolled
ACTME
Phase 1/2 Unknown
34 enrolled
OpACIN-neo
Phase 2 Unknown
186 enrolled
Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1
Phase 4 Unknown
50 enrolled
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
Phase 2 Unknown
52 enrolled
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Phase 2 Unknown
441 enrolled
Microbiome Immunotherapy Toxicity and Response Evaluation
Unknown
1,800 enrolled
REFINE
Phase 2 Unknown
160 enrolled
Nivo-TIL
Phase 1/2 Unknown
11 enrolled
CHARLI
Phase 1/2 Unknown
72 enrolled
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
Phase 1 Unknown
219 enrolled
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC
Phase 1/2 Unknown
42 enrolled
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
Unknown
400 enrolled
Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors
Phase 1 Unknown
30 enrolled
SONIMEL01
Phase 1/2 Unknown
21 enrolled
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics
Unknown
130 enrolled
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
Phase 2 Unknown
40 enrolled
NIBIT-ML1
Phase 2 Unknown
184 enrolled
Polish Microbiome Map
Unknown
1,160 enrolled
The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma
Phase 2 Unknown
52 enrolled
ENIgMA
Phase 1 Unknown
21 enrolled